Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...
Invitae has collected a de novo clearance from the FDA for a blood test designed to detect hundreds of potential genetic markers to help evaluate whether a person carries an increased risk of ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback